The global constrained peptide drugs market revenue has been forecasted from 2024 to 2040, following the earliest launch of the first constrained peptide drug in the market.

The market size is anticipated to be $0.06 billion in 2024 and is expected to reach $17.38 billion in 2040, growing at a CAGR of 38.94% during the forecast period 2025-2040.

Market Lifecycle Stage

The global constrained peptide drugs market is anticipated to witness tremendous growth during the forecast period 2025-2040, largely fuelled by the promise of a novel breakthrough constrained peptide pipeline, which is no longer restricted to receptor targets. Advancements in chemical technologies, the therapeutics’ success of commercialized synthetic peptides in recent years, and the affordable pricing being realized by these biomolecules in a wide range of diseases are some additional factors attributing to the projected growth in the forecast period.

Impact

The impact analysis for the factors that significantly affect the market, namely, drivers, restraints, and opportunities, has been provided on a short-term and long-term basis. The short-term assessment considers the period between 2020 and 2025, and the long-term assessment considers the period between 2026 and 2040. Key developments and strategies that have been undertaken by some of the key players in this market have been accounted for evaluation of the impact analysis. Further, these key developments have been assessed to understand the future scope of integrating advancing technologies to enable superior outcomes. Additionally, approvals and launches from companies and patent bodies have also been considered while evaluating the dynamics of the global constrained peptide drugs market.

Impact of COVID-19

In December 2019, Wuhan, a city in the Hubei region of China, was the site of the first detection of the COVID-19 outbreak. Following the classification of COVID-19 as novel pneumonia due to a cluster of unexplained pneumonia cases, efforts to pinpoint the culprit causing the outbreak and outline its genomic sequence got underway right once. The virus has already spread to every country on the globe, and researchers, governments, and business leaders are working to find answers to the crisis at a scale and speed that has never been seen. Testing for SARS-CoV-2 in the populace is one of the main steps that has been put into place globally, among many other measures used to stop the spread of the disease.

The global constrained peptide drugs market is a research-oriented market, having a majority of products in clinical trial stages. It primarily consists of clinical-stage biopharmaceutical companies and global biopharmaceutical companies such as Bicycle Therapeutics PLC, Protagonist Therapeutics, Inc., Aileron Therapeutics, Inc., Polyphor, and Santhera Pharmaceuticals Holding. Since most of the products are in the clinical phase of drug development, constrained peptide drug companies had a low impact on the COVID-19 pandemic.

Although clinical trials were brought to pause because of the lockdowns imposed by governments across the world, causing a delay in the clinical trial timeline, and volunteers and patients were also not able to participate in the clinical trials due to the lockdown; however, few companies took the opportunity of the pandemic and initiated the development of potential drugs against COVID-19. For instance, UCB Pharma participated in the COVID-19 Moonshot, an initiative to expedite the development of an anti-viral for COVID-19. The company’s Phase III investigational molecule Zilucoplan is being studied for acute respiratory distress syndrome associated with COVID-19. Another company, Polyphor Limited, is evaluating Balixafortide, a constrained peptide drug, against COVID-19 as it demonstrated strong efficacy in in-vitro models.

During the pre-COVID-19 period, the global constrained peptide drugs market observed 38 significant key developments. Out of the 38 key developments, the majority were funding activities, primarily focused on the development of novel antibiotics and support clinical trials of certain drugs in clinical phases. For example, in May 2019, Innosuisse awarded Polyphor Ltd. and the University of Zurich to escalate the development of novel antibiotics for treating infections caused by gram-negative bacteria. Furthermore, seven synergistic activities were undertaken in the global constrained peptide drugs market before COVID-19.

Market Segmentation:

Segmentation 1: by Peptide Type

• Disulfide-Rich Peptides (DRPs)
• Cyclic Peptides

Based on peptide type, the disulfide-rich peptides (DRPs) segment is anticipated to dominate the global constrained peptide drugs market in 2040 as the segment includes the pipeline-constrained peptide with either limited existing treatment options or no approved drugs for the disease.

Segmentation 2: by Region

• North America
• Europe
• Asia-Pacific

The North America region is anticipated to dominate the global constrained peptide drugs market (by region) during the forecast period 2025-2040. The reasons contributing to the high demand for constrained peptide drugs in North America are the increasing prevalence of target indications and the early launch of pipeline products in the U.S. and Canada.

Segmentation 3: by Potential Product

• BT5528
• Rusfertide (PTG-300)
• PN-943
• PN-235
• Zilucoplan (RA101495)

Segmentation 4: by Company

• Aileron Therapeutics, Inc.
• Bicycle Therapeutics plc
• Spexis AG
• Protagonist Therapeutics Inc.
• Santhera Pharmaceuticals
• Union Chimique Belge S.A. (UCB)
• Creative Peptides
• Biosynth (Pepscan)
• Pepticom Ltd.
• PeptiDream, Inc.
• Bio-Synthesis Inc
• CPC Scientific Inc.
• Circle Pharma
• Zealand Pharma
• Chugai Pharmaceutical Co., Ltd.

Based on the company, the global constrained peptide drugs market is dominated by 15 major companies.

Recent Developments in the Global Constrained Peptide Drugs Market

• In August 2021, Protagonist Therapeutics Inc. declared the resolution of its collaboration agreement with Zealand Pharma through the reduction of future milestone payments, sales milestones, and royalties owed to Zealand Pharma regarding Protagonist Therapeutics Inc.’s product candidate rusfertide under the terms of the 2012 collaboration agreement between the companies.
• In April 2021, Union Chimique Belge S.A. (UCB) anticipated the release of phase 3 key results for generalized myasthenia gravis (gMG) in the fourth quarter of 2021 and discontinued further development of zilucoplan for immune-mediated necrotizing myopathy (IMNM).
• In September 2021, Polyphor Limited and EnBiotix announced the successful closing of the purchase agreement for EnBiotix to acquire the inhaled antibiotic murepavadin.
• In November 2020, Pepscan Therapeutics B.V. was granted a license for the use of the proprietary CLIPS technology offered by Bicycle Therapeutics plc. The peptide-constraining technology would further help in the development of the company’s products named BT1718 and THR-149.
• In June 2020, Santhera Pharmaceuticals secured a financing commitment of up to $22.1 million from a fund managed by Highbridge Capital Management.

Demand – Drivers and Limitations

The following are the demand drivers for the global constrained peptide drugs market:

• Enhanced Binding Affinity and Cellular Uptake
• Development of Synthetic Constraining Method
• Limitations with Conventional Peptides
• Increasing Government and Private Funding

The market is expected to face some limitations due to the following challenges:

• Increased Competition from Biologics
• Risk of Immunogenic Effects and Unsatisfactory ADME Properties

How can this report add value to an organization?

Workflow/Innovation Strategy: The global constrained peptide drugs market has been segmented (by product) into five candidates, i.e., BT5528, Rusfertide (PTG-300), Zilucoplan (RA101495), PN-235, and PN-943. Over the past decade, peptide drug discovery and development has witnessed a renaissance and scientific thrust as the industry has come to acknowledge the capability of peptide therapeutics in addressing unmet medical needs and the potential of this class of molecules to become a significant accompaniment or even favored alternative treatment to biologics and small molecules.

Peptide therapeutics have demonstrated a novel and selective yet safe mode of action for a wide range of indications. The existing and future development of constrained peptide drugs will continue to burgeon upon the strengths of constrained peptides and innovative technologies employed in the discovery and development, including peptide drug conjugates, multifunctional peptides, and cell-penetrating peptides. Furthermore, limitations associated with presently available peptides have resulted in an urgent need for new design, administration, and synthesis in peptide therapeutics, thereby leading to advancements in the development of constrained peptides.

Growth/Marketing Strategy: Constrained peptides provide noteworthy advantages over linear peptides. An increase in interest in the field of constrained peptides due to the properties they offer led to advancements in peptide synthesis technologies. Companies such as PeptiDream Inc., Pepticom Ltd., Bicycle Therapeutics plc, and Polyphor Limited offer proprietary drug development and constrained peptide synthesis technologies. PeptiDream Inc.’s proprietary Peptide Discovery Platform System (PDPS) technology is used to synthesize synthetic non-native peptide libraries expeditiously, which helps in identifying peptides that can be used as potential drugs for a disease.

Competitive Strategy: Key players in the global constrained peptide drugs market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global constrained peptide drugs market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

The post Constrained Peptide Drugs Market – A Global and Regional Analysis: Focus on Peptide Type, Product, and Region-Wise Analysis – Analysis and Forecast, 2024-2040 first appeared on CRI Report.

Market Segmentation

• Propulsion Type: All-Electric Propulsion, Hybrid-Electric Propulsion

Regional Segmentation

• North America: U.S. and Canada
• South America
• Europe: U.K., Germany, France, Russia, Netherlands, and Rest-of-Europe
• Middle East and Africa
• Asia-Pacific: China, Japan, India, Australia, Singapore, and Rest-of-Asia-Pacific

Key Companies Profiled

3W International GmbH, Airbus S.A.S., Boeing, Cranfield Aerospace Solutions, General Electric Company, GKN Aerospace Services Limited, Honeywell International Inc., Israel Aerospace Industries Ltd., Lockheed Martin Corporation, MagniX, Rolls-Royce Holdings plc., Safran S.A., Siemens AG, Raytheon Technologies Corporation, Leonardo S.p.A

How This Report Can Add Value

This report will help with the following objectives:

• A dedicated section focusing on start-up and investment landscape
• Detailed analysis, which includes both value and volume of electric and hybrid-electric propulsion system used on all the aircraft types
• Major Programs of Electric & Hybrid-electric Aircraft Propulsion System Market

Market by Product: Analysis and Forecast: The product section will help the reader understand the different types of electric & hybrid-electric aircraft propulsion system used in several manned, unmanned and eVTOLs aircraft. The players operating in this market are developing innovative offerings and are highly focused on testing as well as demonstrating their propulsion system capabilities.

Key Questions Answered in the Report

• What are the major drivers, challenges, and opportunities behind the demand for the electric & hybrid-electric aircraft propulsion system market during the forecast period 2025-2035?
• Who are the key players in the electric & hybrid-electric aircraft propulsion system market, and what is the competitive benchmarking?
• What are the new strategies being adopted by the existing market players to make a mark in the industry?
• How is the electric & hybrid-electric aircraft propulsion system market expected to grow during the forecast period, and what is the anticipated revenue to be generated by the end of 2035?
• What are the trends in the electric & hybrid-electric aircraft propulsion system market across different countries? What are the revenue estimates for 2025 and 2035?
• Which country is expected to contribute the most to the electric & hybrid-electric aircraft propulsion system market during the forecast period?

Electric & Hybrid-Electric Aircraft Propulsion System

Electrically powered model aircraft and unmanned aerial vehicles (UAVs) have been flying since the 1970s. Although, in 1917, the first electrically powered manned tethered helicopter was developed. Moreover, the first ever electrically powered airplane, the MB-E1 was flown in October 1973. Along with this, many other electric-powered airplane prototypes are being developed and tested to enhance the air travel experience.

Hybrid-electric propulsion combines a conventional internal combustion engine system with an electric propulsion system. This type of propulsion system does not emit harmful components in the air, which reduces the total pollution levels raised due to air travel. Hybrid-electric propulsion can be classified into series- hybrid propulsion and parallel-hybrid propulsion.

Electric & Hybrid-Electric Aircraft Propulsion System Industry Overview

Governments are investing a significant amount of their resources in developing high-speed propulsion system designs such as ramjet and scramjet propulsion systems. High speed aircraft use air-breathing ramjet and scramjet engines that allow them to hover at extremely high speeds.

The global Electric & Hybrid-Electric Aircraft Propulsion System market is estimated to reach $74.90 billion in 2035, at a compound annual growth rate (CAGR) of 18.39% during the forecast period 2025-2035.

Market Segmentation

Electric & Hybrid-Electric Aircraft Propulsion System Market by Propulsion Type

Hybrid-Electric Propulsion segment is expected to dominate the global the electric & hybrid-electric aircraft propulsion system market, on account of high investments that are expected to be attained in the future due to the high adoption rate in the commercial aviation industry.

Electric & Hybrid-Electric Aircraft Propulsion System Market by Region

North America is expected to dominate the global electric & hybrid-electric aircraft propulsion system market during the forecast period. The research and development of next-gen aircraft in the region are growing at a significant pace, which in turn is expected to raise the demand for Electric & Hybrid-electric Aircraft Propulsion Systems in the coming years.

Key Market Players and Competition Synopsis

3W International GmbH, Airbus S.A.S., Boeing, Cranfield Aerospace Solutions, General Electric Company, GKN Aerospace Services Limited, Honeywell International Inc., Israel Aerospace Industries Ltd., Lockheed Martin Corporation, MagniX, Rolls-Royce Holdings plc., Safran S.A., Siemens AG, Raytheon Technologies Corporation, Leonardo S.p.A

The companies that are profiled in the report have been selected post undergoing in-depth interviews with experts and understanding details around companies such as product portfolio, annual revenues, market penetration, research and development initiatives, and domestic and international presence in the electric & hybrid-electric aircraft propulsion system market.

Accordingly, a structured approach is followed which include segmenting pool of players under three mutually exclusive and collectively exhaustive parts, holding a 100% pie of the market, as mentioned below:

Top Segment Players – These are leading original equipment manufacturers (OEMs), covering ~60% of the presence in the market.

Other Segment Players – These are component providers, covering ~40% of the presence in the market.

However, if a company is not part of the above pool, it has been well represented across different sections of the report (wherever applicable).

Electric Bikes Market in India 2021

The post Electric & Hybrid-Electric Aircraft Propulsion System Market – A Global and Regional Analysis: Focus on Product and Country – Analysis and Forecast, 2025-2035 first appeared on CRI Report.